Indeed, CEBPA and DDX41 are included in myeloid neoplasms with germline predisposition without a pre‐existing platelet disorder; FANCA is listed in the category of genes mutated in myeloid neoplasms associated with bone marrow failure syndromes; JAK2 is included in emerging disorders with germline predisposition; and, finally, LYST and ERBB4 have not been reported yet in such classifications. This evidence concerns the gene CEBPA and blood platelet disease.